Gilead's Cayston Picks Up Panel Endorsement, But Not Based On Data

It was the orphan setting and urgent need for new therapies to treat the respiratory and pulmonary symptoms of cystic fibrosis that led FDA's Anti-Infective Drugs Advisory Committee to support approval of Gilead's Cayston (aztreonam lysine)